MRK—Keytruda data in first-line H&N cancer from KEYNOTE-048 study: https://finance.yahoo.com/news/merck-keytruda-pembrolizumab-significantly-improved-143000250.html Keytruda monotherapy bests chemo in OS for PD-L1+ subgroup even though ORR and PFS were worse than chemo arm in that subgroup! Keytruda + chemo fails to meet prespecified thresholds.